Min­eralys emerges with a new take on an old idea for the treat­ment of hy­per­ten­sion and $40M to play with

Al­dos­terone, a hor­mone linked to in­creased blood pres­sure, has long been a tar­get of in­ter­est for the treat­ment of hy­per­ten­sion, but se­lec­tiv­i­ty has been a chal­lenge. Now a new com­pa­ny has emerged from stealth to im­prove where oth­ers have failed.

Min­eralys Ther­a­peu­tics un­cloaked ear­ly Mon­day morn­ing with $40 mil­lion in Se­ries A funds to prep their lead can­di­date —  a se­lec­tive al­dos­terone syn­thase in­hibitor li­censed from Japan’s Mit­subishi Tan­abe — for a piv­otal study. The com­pa­ny was launched by Catalys Pa­cif­ic, the VC firm founder BT Slings­by put to­geth­er to cre­ate new biotechs around Japan­ese in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER